Saturday 17 October 2026
Export MLEC’s income statement to Excel — free account
Moolec Science SA
MLEC Healthcare Biotechnology
In the quarter to December 2025, revenue grew 948.4%, EPS fell 20.0% and free cash flow grew 4.48%, each against the same quarter a year earlier.
1.68
0.19
−10.16%
Follow MLEC
Moolec Science SA (MLEC) P/E ratio
Moolec Science SA has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 409× (June 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| 3 more quarters | Free account |
Against its own ten years
Low 0.0×
High 409×
Ten-year median
0.0×
Current reading's percentile
76
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NEXI NexImmune, Inc. compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| CYTOF Altamira Therapeutics Ltd. compare | n/m |
| SPRC SciSparc Ltd. compare | n/m |
| CARM Carisma Therapeutics Inc. compare | n/m |
| MLEC Moolec Science SA | n/m |
| ITRMF Iterum Therapeutics PLC compare | n/m |
| ABPO Abpro Holdings Inc. compare | 0.2× |
| PTIX Atrinsic Inc. compare | 0.3× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)